--- title: "Akebia Therapeutics' (AKBA) \"Buy\" Rating Reaffirmed at HC Wainwright" description: "HC Wainwright has reaffirmed a \"buy\" rating for Akebia Therapeutics (NASDAQ:AKBA) with a target price of $7.50, indicating a potential upside of 343.79% from its current price of $1.69. The company re" type: "news" locale: "en" url: "https://longbridge.com/en/news/231941957.md" published_at: "2025-03-15T13:00:50.000Z" --- # Akebia Therapeutics' (AKBA) "Buy" Rating Reaffirmed at HC Wainwright > HC Wainwright has reaffirmed a "buy" rating for Akebia Therapeutics (NASDAQ:AKBA) with a target price of $7.50, indicating a potential upside of 343.79% from its current price of $1.69. The company reported a quarterly loss of $0.10 per share, missing estimates, but revenue of $46.50 million exceeded expectations. Recent insider sales and institutional investments have been noted, with 33.92% of shares held by institutional investors. Akebia focuses on developing treatments for kidney diseases, with its lead product in Phase III trials for anemia due to chronic kidney disease. Akebia Therapeutics (NASDAQ:AKBA - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $7.50 target price on the biopharmaceutical company's stock. HC Wainwright's price target would indicate a potential upside of 343.79% from the stock's current price. Get **Akebia Therapeutics** alerts: - Akebia Therapeutics Surges on FDA Approval for Anemia Treatment Separately, StockNews.com cut Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, March 6th. **Check Out Our Latest Stock Analysis on AKBA** ## Akebia Therapeutics Stock Down 12.4 % Shares of AKBA opened at $1.69 on Friday. Akebia Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $2.48. The company's fifty day moving average is $2.01 and its two-hundred day moving average is $1.78. The firm has a market cap of $368.73 million, a PE ratio of -7.35 and a beta of 0.94. Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its earnings results on Thursday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.05). The company had revenue of $46.50 million during the quarter, compared to analysts' expectations of $37.36 million. As a group, equities research analysts anticipate that Akebia Therapeutics will post -0.3 earnings per share for the current year. ## Insider Activity at Akebia Therapeutics In related news, SVP Steven Keith Burke sold 50,506 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $106,062.60. Following the sale, the senior vice president now directly owns 816,234 shares in the company, valued at approximately $1,714,091.40. This trade represents a 5.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Richard C. Malabre sold 30,202 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total value of $63,424.20. Following the transaction, the chief accounting officer now directly owns 280,248 shares in the company, valued at $588,520.80. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 280,579 shares of company stock worth $589,216. 4.10% of the stock is currently owned by corporate insiders. ## Institutional Inflows and Outflows Several institutional investors and hedge funds have recently made changes to their positions in the company. SRS Capital Advisors Inc. purchased a new position in Akebia Therapeutics in the 4th quarter valued at about $26,000. PDS Planning Inc acquired a new position in shares of Akebia Therapeutics in the fourth quarter worth about $28,000. Mariner LLC purchased a new position in Akebia Therapeutics in the fourth quarter valued at about $28,000. Cibc World Markets Corp purchased a new position in Akebia Therapeutics in the fourth quarter valued at about $37,000. Finally, Aquatic Capital Management LLC acquired a new stake in Akebia Therapeutics during the 4th quarter valued at approximately $47,000. 33.92% of the stock is currently owned by hedge funds and other institutional investors. ## Akebia Therapeutics Company Profile (Get Free Report) Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. ## Recommended Stories - Five stocks we like better than Akebia Therapeutics - Earnings Per Share Calculator: How to Calculate EPS - Market Momentum Shifts, But These 3 Stocks Are Built to Last - Industrial Products Stocks Investing - D-Wave Quantum Stock Jumps on "Quantum Supremacy" News - Why Invest in 5G? How to Invest in 5G Stocks - How Taiwan Semiconductor’s U.S. Move Could Shift Chipmaking *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Akebia Therapeutics Right Now? Before you consider Akebia Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list. While Akebia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [AKBA.US - Akebia Therap](https://longbridge.com/en/quote/AKBA.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Akebia Therapeutics 在峰会上重点介绍 VAFSEO 的透析推广、每周三次剂量计划以及罕见肾病研发管线 | Akebia Therapeutics 在古根海姆新兴前景生物科技峰会上强调了其商业优先事项和产品管线，重点关注其贫血药物 VAFSEO 在美国透析中心的采用情况。首席执行官 John Butler 强调了公司对肾病治疗的承诺，并指出 VA | [Link](https://longbridge.com/en/news/275778572.md) | | 荷兰国际集团 NV 迄今为止以平均价格€23.36 回购了 27,077,073 股 | ING Groep NV 已回购总计 27,077,073 股股票，平均价格为每股 23.36 欧元，作为其持续回购计划的一部分，总金额约为 632,457,091 欧元 | [Link](https://longbridge.com/en/news/275414222.md) | | Enliven Therapeutics (NASDAQ:ELVN) 的一位董事出售了价值 32,201.40 美元的股票 | Enliven Therapeutics 董事 Richard Heyman 以平均价格 26.18 美元出售了 1,230 股公司股票，交易总额为 32,201.40 美元，减少了 5.15% 的持股比例。出售后，他持有 22,647 股 | [Link](https://longbridge.com/en/news/276398227.md) | | GSA Capital Partners LLP 增加了对 Edgewise Therapeutics, Inc. $EWTX 的持股 | GSA Capital Partners LLP 在第三季度将其在 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) 的持股增加了 315.2%，目前持有 113,243 股，价值 184 万美元。其他对冲 | [Link](https://longbridge.com/en/news/276119404.md) | | Readystate 资产管理公司出售了 288,480 股 Celldex Therapeutics, Inc.的股票$CLDX | Readystate Asset Management LP 已显著减少在塞德斯医疗的股份，减少幅度达到 86.1%，在第三季度出售了 288,480 股。出售后，该公司目前持有 46,520 股，估值约为 120 万美元。其他投资者也对塞 | [Link](https://longbridge.com/en/news/276326472.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.